Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DYN Stock Forecast 2025-2026
$20.28
Current Price
$2.90B
Market Cap
Buy 13
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to DYN Price Targets
+146.5%
To High Target of $50.00
+82.4%
To Median Target of $37.00
-45.8%
To Low Target of $11.00
DYN Price Momentum
-7.4%
1 Week Change
+10.5%
1 Month Change
-31.3%
1 Year Change
-13.9%
Year-to-Date Change
-31.8%
From 52W High of $29.72
+218.9%
From 52W Low of $6.36
📊 TOP ANALYST CALLS
Did DYN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Dyne Therapeutics is one of their latest high-conviction picks.
Latest DYN Stock Price Targets & Analyst Predictions
Based on our analysis of 20 Wall Street analysts, DYN has a bullish consensus with a median price target of $37.00 (ranging from $11.00 to $50.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $20.28, the median forecast implies a 82.4% upside. This outlook is supported by 13 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Debjit Chattopadhyay at Guggenheim, projecting a 146.5% upside. Conversely, the most conservative target is provided by Andreas Argyrides at Oppenheimer, suggesting a 45.8% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DYN Analyst Ratings
13
Buy
3
Hold
0
Sell
DYN Price Target Range
Low
$11.00
Average
$37.00
High
$50.00
Current: $20.28
Latest DYN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DYN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 14, 2025 | JP Morgan | Tessa Romero | Neutral | Maintains | $17.00 |
| Nov 12, 2025 | Oppenheimer | Andreas Argyrides | Perform | Maintains | $11.00 |
| Nov 6, 2025 | RBC Capital | Luca Issi | Outperform | Maintains | $30.00 |
| Nov 6, 2025 | HC Wainwright & Co. | Ananda Ghosh | Buy | Maintains | $46.00 |
| Oct 10, 2025 | Oppenheimer | Andreas Argyrides | Perform | Downgrade | $13.00 |
| Aug 25, 2025 | Raymond James | Martin Auster | Strong Buy | Upgrade | $35.00 |
| Aug 6, 2025 | Oppenheimer | Andreas Argyrides | Outperform | Maintains | $13.00 |
| Jul 31, 2025 | Stifel | Paul Matteis | Buy | Maintains | $36.00 |
| Jul 29, 2025 | RBC Capital | Luca Issi | Outperform | Maintains | $23.00 |
| Jul 29, 2025 | Raymond James | Martin Auster | Outperform | Reiterates | $31.00 |
| Jul 29, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $38.00 |
| Jul 15, 2025 | JP Morgan | Tessa Romero | Neutral | Maintains | $9.00 |
| Jun 26, 2025 | Jones Trading | Catherine Novack | Buy | Initiates | $30.00 |
| Jun 18, 2025 | Baird | Brian Skorney | Outperform | Maintains | $32.00 |
| Jun 18, 2025 | Guggenheim | Debjit Chattopadhyay | Buy | Reiterates | $50.00 |
| Jun 17, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $50.00 |
| Jun 11, 2025 | Raymond James | Michael Freeman | Outperform | Assumes | $37.00 |
| Jun 2, 2025 | Oppenheimer | Andreas Argyrides | Outperform | Assumes | $34.00 |
| May 9, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $38.00 |
| May 9, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $50.00 |
Dyne Therapeutics Inc. (DYN) Competitors
The following stocks are similar to Dyne Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Dyne Therapeutics Inc. (DYN) Financial Data
Dyne Therapeutics Inc. has a market capitalization of $2.90B with a P/E ratio of -6.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -60.7%.
Valuation Metrics
Market Cap
$2.90B
Enterprise Value
$2.23B
P/E Ratio
-6.0x
PEG Ratio
0.3x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+27.3%
Current Ratio
13.5x
Debt/Equity
17.4x
ROE
-60.7%
ROA
-34.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Dyne Therapeutics Inc. (DYN) Business Model
About Dyne Therapeutics Inc.
What They Do
Develops therapies for genetically-driven muscle diseases.
Business Model
Dyne Therapeutics operates in the biopharmaceutical sector, utilizing its proprietary FORCE platform to deliver RNA therapies directly to affected muscle tissues. This targeted approach enhances therapeutic effectiveness while minimizing off-target effects, allowing the company to address unmet medical needs in muscle disorders, particularly in conditions where treatment options are scarce.
Additional Information
The company is focused on innovation within the healthcare and biotechnology sectors, contributing to the development of novel drugs and advancing therapeutic possibilities. Dyne Therapeutics aims to improve the quality of life for patients with muscular dystrophies and similar conditions through precision medicine and strategic research initiatives.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
240
CEO
Mr. John G. Cox M.B.A.
Country
United States
IPO Year
1993
Website
www.dyne-tx.comDyne Therapeutics Inc. (DYN) Latest News & Analysis
Latest News
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?
4 days ago
Quick Summary
Palo Alto Investors acquired 997,698 shares of DYN in Q3, increasing their position value by $13.5 million from the previous quarter.
Why It Matters
Palo Alto Investors' significant acquisition and increased position value in DYN signals strong confidence in the company's future, potentially driving investor interest and stock performance.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
An analyst note on the biotech sector highlights that a specific company has been overlooked in a recent rally, suggesting potential for growth.
Why It Matters
Positive analyst notes can boost stock prices, indicating potential growth in the biotech sector and signaling that overlooked companies may present buying opportunities.
Source: The Motley Fool
Market Sentiment:
Positive
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
1 month ago
Quick Summary
Topline data from the DELIVER trial of zeleciment rostudirsen (DYNE-251) in DMD is expected in December 2025, potentially supporting U.S. Accelerated Approval submission in Q2 2026.
Why It Matters
The timeline for z-rostudirsen's trial results and potential U.S. approval could significantly impact DYNE Therapeutics' stock value and market position in the DMD treatment landscape.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Dyne Therapeutics, Inc. (Nasdaq: DYN) will present at upcoming investor conferences, focusing on advancements in treating genetically driven neuromuscular diseases.
Why It Matters
Dyne Therapeutics' participation in investor conferences signals potential investor interest and insight into its progress in neuromuscular disease treatments, which may influence stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Dyne Therapeutics' stock is experiencing a record rally, with an analyst suggesting further potential gains following a rival's acquisition at a significant premium.
Why It Matters
Dyne Therapeutics' stock surge signals strong investor interest, and potential for further gains exists due to acquisition dynamics in the sector, indicating heightened market activity and valuation opportunities.
Source: Market Watch
Market Sentiment:
Positive
Quick Summary
Dyne is speculated to be a potential acquisition target following a peer's acquisition at a high premium, indicating increased market interest.
Why It Matters
The acquisition at a high premium signals strong demand in the sector, potentially boosting Dyne's stock as investors anticipate a similar buyout.
Source: The Motley Fool
Market Sentiment:
Positive
Frequently Asked Questions About DYN Stock
What is Dyne Therapeutics Inc.'s (DYN) stock forecast for 2026?
Based on our analysis of 20 Wall Street analysts, Dyne Therapeutics Inc. (DYN) has a median price target of $37.00. The highest price target is $50.00 and the lowest is $11.00.
Is DYN stock a good investment in 2026?
According to current analyst ratings, DYN has 13 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $20.28. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DYN stock?
Wall Street analysts predict DYN stock could reach $37.00 in the next 12 months. This represents a 82.4% increase from the current price of $20.28. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Dyne Therapeutics Inc.'s business model?
Dyne Therapeutics operates in the biopharmaceutical sector, utilizing its proprietary FORCE platform to deliver RNA therapies directly to affected muscle tissues. This targeted approach enhances therapeutic effectiveness while minimizing off-target effects, allowing the company to address unmet medical needs in muscle disorders, particularly in conditions where treatment options are scarce.
What is the highest forecasted price for DYN Dyne Therapeutics Inc.?
The highest price target for DYN is $50.00 from Debjit Chattopadhyay at Guggenheim, which represents a 146.5% increase from the current price of $20.28.
What is the lowest forecasted price for DYN Dyne Therapeutics Inc.?
The lowest price target for DYN is $11.00 from Andreas Argyrides at Oppenheimer, which represents a -45.8% decrease from the current price of $20.28.
What is the overall DYN consensus from analysts for Dyne Therapeutics Inc.?
The overall analyst consensus for DYN is bullish. Out of 20 Wall Street analysts, 13 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $37.00.
How accurate are DYN stock price projections?
Stock price projections, including those for Dyne Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 3:42 PM UTC